Assessing Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Weakness And Strong Longer Term Returns

Tarsus Pharmaceuticals (TARS) has been drawing attention after recent trading swings, with the stock closing at US$59.64 while showing mixed returns over the past month and past 3 months, alongside a positive one year track record.

See our latest analysis for Tarsus Pharmaceuticals.

The share price has been under pressure in recent months, with a 90 day share price return down 18.32% and year to date share price return down 26.16%. At the same time, the 1 year total shareholder return sits at 38.34% and the 3 year total shareholder return is very strong at 226.44%. This suggests earlier investors have still seen substantial gains while recent momentum has faded.

If Tarsus’s swings have you thinking about where else growth stories might emerge in healthcare, it could be a good time to scan 39 healthcare AI stocks.

With Tarsus Pharmaceuticals reporting US$535.08m in revenue, a loss of US$48.27m and trading at US$59.64 with an implied discount to analyst and intrinsic values, the question is simple: is there still a buying opportunity here, or is future growth already priced in?

Most Popular Narrative: 32.2% Undervalued

Against the last close at $59.64, the most followed narrative pegs Tarsus Pharmaceuticals at a fair value of $88.00, framing the recent pullback as a potential valuation gap tied to future cash flow expectations and profitability shifts.

The assumed bearish price target for Tarsus Pharmaceuticals is $88.0, which represents up to two standard deviations below the consensus price target of $95.0. This valuation is based on what can be assumed as the expectations of Tarsus Pharmaceuticals’s future earnings growth, profit margins and other risk factors from analysts on the more bearish end of the spectrum.

Read the complete narrative.

Want to see what kind of revenue curve and margin reset could justify that $88.00 tag at a 6.98% discount rate? The narrative leans on robust earnings expansion, a sharply different margin profile, and a future earnings multiple more commonly associated with faster growing sectors. Curious which assumptions have to hold for that story to work?

Result: Fair Value of $88 (UNDERVALUED)

Have a read of the narrative in full and understand what’s behind the forecasts.

However, there are still clear risks, including reliance on XDEMVY in a competitive eye care market and potential pressure on pricing as payers push harder for discounts.

Find out about the key risks to this Tarsus Pharmaceuticals narrative.

Next Steps

Given the mix of optimism and concern in this story, it makes sense to review the risk reward balance for yourself and decide where you stand. You can start with the 4 key rewards and 1 important warning sign.

Looking for more investment ideas?

If Tarsus has sparked your interest, do not stop here. Broaden your watchlist with other stocks that fit different goals and risk levels.

This article by Simply Wall St is general in nature. We provide commentary based on historical data
and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your
financial situation. We aim to bring you long-term focused analysis driven by fundamental data.
Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.
Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com